Hospital
Phillips Hospital Company LLC
Phillips Hospital Company LLC was paid $3.09M by Medicaid between Jan 2018 and Dec 2024, across 146 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 11% of everything it billed.
33Billing provider infoPHILLIPS HOSPITAL COMPANY LLC
HELENA, AR 72342
HELENA, AR 72342
33aNPI1154392090assigned 01/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.09M
24GClaims208,466
24DCodes billed146
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#22 of 49
Median peer was paid$2.62M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,549 | $469K | |
| 2019 | 35,658 | $559K | |
| 2020 | 28,694 | $408K | |
| 2021 | 31,131 | $527K | |
| 2022 | 29,271 | $534K | |
| 2023 | 32,167 | $459K | |
| 2024incomplete | 11,996 | $134K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 11% | 20,731 | 15,788 | $350K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 11% | 3,971 | 3,238 | $338K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.1% | 4,250 | 3,258 | $250K |
| 70450 | Computed tomography, head or brain; without contrast material | 7.6% | 2,979 | 2,427 | $234K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 1,569 | 1,215 | $162K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.8% | 2,246 | 1,823 | $148K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 23,734 | 17,440 | $135K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.7% | 2,933 | 2,378 | $83K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.2% | 4,182 | 3,372 | $69K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 8,405 | 6,146 | $62K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 3,383 | 2,673 | $58K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 2,586 | 1,922 | $52K |
134 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 2,664 | $46K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 3,104 | $45K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 3,891 | $44K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 7,988 | $42K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 840 | $41K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 1,068 | $40K |
| 80061 | Lipid panel | 1.3% | 3,841 | $39K |
| 84484 | 1.2% | 6,552 | $38K | |
| 83880 | 1.2% | 2,267 | $38K | |
| 71045 | Radiologic examination, chest; single view | 1.2% | 6,109 | $38K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 3,261 | $34K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 664 | $31K |
| 84703 | <1% | 3,625 | $30K | |
| 87430 | <1% | 2,885 | $29K | |
| 86901 | <1% | 1,156 | $26K | |
| 73630 | <1% | 1,284 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,712 | $25K |
| 73560 | <1% | 1,134 | $24K | |
| 81001 | <1% | 8,508 | $24K | |
| 72100 | <1% | 1,021 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 804 | $21K |
| 87040 | <1% | 2,738 | $21K | |
| 74018 | <1% | 1,187 | $20K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,810 | $20K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 897 | $20K |
| 87807 | <1% | 1,784 | $20K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 564 | $18K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 438 | $18K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,966 | $16K |
| 85027 | <1% | 3,083 | $16K | |
| 83690 | <1% | 3,093 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,308 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 356 | $12K |
| 80320 | <1% | 782 | $10K | |
| 84702 | <1% | 1,088 | $10K | |
| 83605 | <1% | 1,470 | $10K | |
| 82962 | <1% | 2,923 | $9K | |
| 73030 | <1% | 562 | $9K | |
| 73130 | <1% | 450 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 59 | $7K |
| 87077 | <1% | 1,024 | $7K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 569 | $7K |
| 86850 | <1% | 918 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,367 | $6K |
| 87081 | <1% | 757 | $6K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 38 | $6K |
| 82553 | <1% | 921 | $5K | |
| 73610 | <1% | 332 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 483 | $5K |
| 72040 | <1% | 206 | $5K | |
| 83735 | <1% | 1,327 | $5K | |
| 86762 | <1% | 297 | $5K | |
| 81005 | <1% | 2,601 | $5K | |
| 87186 | <1% | 1,024 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,715 | $5K |
| 71020 | <1% | 335 | $5K | |
| 80076 | <1% | 476 | $5K | |
| 86900 | <1% | 1,159 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,218 | $4K |
| 82550 | <1% | 1,029 | $4K | |
| 85730 | <1% | 999 | $4K | |
| 85610 | <1% | 1,660 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 134 | $3K |
| 86592 | <1% | 704 | $3K | |
| 87205 | <1% | 932 | $3K | |
| 71010 | <1% | 433 | $3K | |
| 86703 | <1% | 152 | $3K | |
| 85378 | <1% | 485 | $2K | |
| 82947 | <1% | 499 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 634 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 15 | $2K |
| 80050 | General health panel | <1% | 45 | $2K |
| 82150 | <1% | 431 | $2K | |
| 80143 | <1% | 104 | $1K | |
| 80179 | <1% | 91 | $1K | |
| 73502 | <1% | 74 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 39 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 39 | $1K |
| 73110 | <1% | 88 | $1K | |
| 71250 | <1% | 15 | $1K | |
| 87340 | <1% | 113 | $1K | |
| 93971 | <1% | 30 | $1K | |
| 72070 | <1% | 61 | $1K | |
| 87070 | <1% | 154 | $1K | |
| 82728 | <1% | 64 | $997.71 | |
| 84439 | <1% | 92 | $964.60 | |
| 85660 | <1% | 140 | $939.85 | |
| 84436 | <1% | 125 | $889.30 | |
| 87210 | <1% | 141 | $732.70 | |
| 86803 | <1% | 44 | $709.79 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 61 | $700.29 |
| 74000 | <1% | 39 | $631.28 | |
| 82565 | <1% | 66 | $591.70 | |
| 84480 | <1% | 40 | $560.95 | |
| 85379 | <1% | 98 | $558.82 | |
| 97001 | <1% | 14 | $543.84 | |
| 81025 | <1% | 91 | $532.77 | |
| 82677 | <1% | 14 | $527.43 | |
| 74010 | <1% | 33 | $525.00 | |
| 80164 | <1% | 17 | $502.24 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $452.77 |
| 74021 | <1% | 14 | $375.79 | |
| 82105 | <1% | 14 | $365.72 | |
| 82803 | <1% | 44 | $359.19 | |
| 84520 | <1% | 64 | $334.29 | |
| 86336 | <1% | 14 | $332.43 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 94 | $312.48 |
| 82607 | <1% | 28 | $281.48 | |
| 36600 | <1% | 27 | $278.11 | |
| 70360 | <1% | 28 | $272.28 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,591 | $259.87 |
| 83540 | <1% | 36 | $249.75 | |
| 81003 | <1% | 167 | $243.88 | |
| 82746 | <1% | 14 | $232.68 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 139 | $219.21 |
| 84550 | <1% | 61 | $207.65 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 45 | $174.03 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 90 | $147.14 |
| 85651 | <1% | 41 | $121.68 | |
| 81002 | <1% | 52 | $117.12 | |
| 71271 | <1% | 16 | $116.60 | |
| 82270 | <1% | 30 | $55.68 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 77 | $43.52 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 175 | $34.84 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14 | $29.83 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 623 | $6.65 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 87 | $5.92 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,523 | $0.02 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 71 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 204 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 296 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 30 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 14 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARSHALL, WILLIAM (ATTORNEY)
| Provider | Location | Paid |
|---|---|---|
| Phillips Clinic Company, LLC | Helena, AR | $521K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.